Minerva Neurosciences, Inc.
NCM: NERVLive Quote
📈 ZcoreAI Score
Our AI model analyzes Minerva Neurosciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get NERV Z-Score →About Minerva Neurosciences, Inc.
Healthcare
Biotechnology
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
📊 Fundamental Analysis
Minerva Neurosciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
At a current price of $5.51, NERV currently sits at the 38th percentile of its 52-week range (Range: $1.30 - $12.46).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$238.44M
Trailing P/E
--
Forward P/E
-11.48
Beta (5Y)
-0.21
52W High
$12.46
52W Low
$1.30
Avg Volume
236K
Day High
Day Low